All Posts: News Release
-
Georgetown Lombardi Announces 2025 Gala Co-Chairs
Georgetown University’s Lombardi Comprehensive Cancer Center today announced that philanthropist and business executive Sherrie Beckstead and Emmy award-winning sportscaster and community advocate Wes Hall will serve as the 37th annual Lombardi Gala co-chairs.
Category: News Release
-
Investigational Drug Shows Promise in a Clinical Trial for Lung Cancers With ALK Mutations
Early signals from phase 1 of the ALKOVE-1 clinical trial suggest potential benefit from the use of an investigational drug called NVL-655 in people whose non-small cell lung cancer has alterations in a gene called ALK.
Category: News Release
-
Countdown to BellRinger: 100 Days Until the Community Bike Ride to End Cancer
Thursday, July 19, 2024, marks 100 days until BellRinger, a bike ride and community movement to end cancer. With efforts to build teams of Riders and fundraising gearing up quickly, BellRinger will take place on October 26, 2024, bringing together Riders of all levels: avid cyclists, casual riders, and people who simply hate cancer – all united in their desire to support cancer research at Georgetown University’s Lombardi Comprehensive Cancer Center, DC’s only cancer center federally designated by the National Cancer Institute.
Category: News Release
-
Increasing Use and Awareness of Oral Nicotine Pouches Detailed
A rigorous, comprehensive synthesis of evidence from 62 studies related to the use of oral nicotine pouches by Georgetown University’s Lombardi Comprehensive Cancer Center scientists and colleagues provides a much-needed assessment of how these products could lead to potential harmful consequences if used by young people.
Category: News Release
-
Addressing Cancer Screening Behaviors in the Muslim Community in Washington
An important study has revealed crucial insights into the cancer screening behaviors of Muslims in the Washington, D.C., area, highlighting the influence of cultural and religious beliefs on health practices.
Category: News Release
-
Case Study Reveals Important New Details About Rare Second Cancers Related to CAR-T Therapy
A new, detailed analysis of a patient’s second cancer after receiving CAR-T therapy for the initial cancer provides rare but important insights intended to offer helpful guidance for oncologists and pathologists about the clinical presentation and pathologic features involved in a CAR-T related second cancer.
Category: News Release
-
Experimental Therapy Shows Promise in Pancreatic Cancer Clinical Trial
Clinicians at Georgetown University’s Lombardi Comprehensive Cancer Center reported promising preliminary findings based on outcomes in the first six patients with metastatic pancreatic cancer enrolled in a phase 2 clinical trial of the experimental drug BXCL701 in combination with the immunotherapy drug pembrolizumab (Keytruda). Immunotherapy drugs alone have not shown to be responsive to pancreatic cancer.
Category: News Release
-
Georgetown’s Cancer Center Awarded Top Designation by Federal Government
The National Cancer Institute (NCI), a part of the National Institutes of Health, has awarded its most prestigious designation — “comprehensive cancer center” status — to Georgetown University‘s Lombardi Comprehensive Cancer Center in recognition of its high-impact research, community outreach and cancer care. Georgetown Lombardi is the only such center in the Washington area.
Category: News Release
-
New Study: Analysis Supports New Recommendation to Begin Mammogram Screening at 40
Georgetown Lombardi’s Jeanne Mandelblatt, MD, MPH, and Amy Trentham-Dietz, PhD, of University of Wisconsin Carbone Cancer Center, were lead authors of a study informing the updated final recommendation of the United States Preventive Services Task Force regarding breast cancer screening, released April 30
Category: News Release
-
The Aspirin Conundrum: Navigating Negative Results, Age, Aging Dynamics and Equity
A new study examining the role of aspirin in breast cancer treatment reveals critical issues related to health equity and aging that have broad implications for cancer and other disease intervention trials, say researchers from Georgetown University’s Lombardi Comprehensive Cancer Center. They outline their concerns in an editorial accompanying the study’s findings published April 29 in the JAMA.
Category: News Release